Metropolitan Life Insurance Company (MetLife)’s Eagle Pharmaceuticals, Inc. EGRX Stock Holding History

Metropolitan Life Insurance Company (MetLife)’s Portfolio EGRX Stock Details EGRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q4	–	Sell	-556	Closed	-$8.77K	–	2401
2023 Q3	$8.77K	Hold	556	–	–	﹤0.01%	2268
2023 Q2	$10.8K	Hold	556	–	–	﹤0.01%	2258
2023 Q1	$15.8K	Sell	556 -206	-27%	-$6.12K	﹤0.01%	1995
2022 Q4	$22.3K	Hold	762	–	–	﹤0.01%	1959
2022 Q3	$20.1K	Hold	762	–	–	﹤0.01%	2025
2022 Q2	$33.9K	Hold	762	–	–	﹤0.01%	1742
2022 Q1	$37.7K	Sell	762 -2,777	-78%	-$133K	﹤0.01%	1746
2021 Q4	$180K	Hold	3,539	–	–	﹤0.01%	2100
2021 Q3	$197K	Hold	3,539	–	–	﹤0.01%	2081
2021 Q2	$151K	Hold	3,539	–	–	﹤0.01%	2352
2021 Q1	$148K	Hold	3,539	–	–	﹤0.01%	2218
2020 Q4	$165K	Hold	3,539	–	–	﹤0.01%	2063
2020 Q3	$150K	Hold	3,539	–	–	﹤0.01%	1957
2020 Q2	$170K	Buy	3,539 +26	+0.7%	+$1.3K	﹤0.01%	1913
2020 Q1	$162K	Hold	3,513	–	–	﹤0.01%	1721
2019 Q4	$211K	Hold	3,513	–	–	﹤0.01%	1887
2019 Q3	$199K	Hold	3,513	–	–	﹤0.01%	1882
2019 Q2	$196K	Hold	3,513	–	–	﹤0.01%	1901
2019 Q1	$177K	Hold	3,513	–	–	﹤0.01%	1975
2018 Q4	$142K	Hold	3,513	–	–	﹤0.01%	2045
2018 Q3	$244K	Hold	3,513	–	–	﹤0.01%	1873
2018 Q2	$266K	Buy	3,513 +642	+22%	+$40.4K	﹤0.01%	1754
2018 Q1	$151K	Buy	2,871 +265	+10%	+$15.4K	﹤0.01%	2065
2017 Q4	$139K	Sell	2,606 -3,024	-54%	-$168K	﹤0.01%	2123
2017 Q3	$336K	Sell	5,630 -252	-4%	-$15.2K	﹤0.01%	1954
2017 Q2	$464K	Sell	5,882 -354	-6%	-$28.9K	﹤0.01%	1746
2017 Q1	$517K	Hold	6,236	–	–	﹤0.01%	1631
2016 Q4	$495K	Hold	6,236	–	–	﹤0.01%	1735
2016 Q3	$437K	Hold	6,236	–	–	﹤0.01%	1787
2016 Q2	$242K	Hold	6,236	–	–	﹤0.01%	2196
2016 Q1	$253K	Hold	6,236	–	–	﹤0.01%	2031
2015 Q4	$553K	Hold	6,236	–	–	﹤0.01%	1563
2015 Q3	$462K	Sell	6,236 -18	-0.3%	-$1.5K	﹤0.01%	1694
2015 Q2	$506K	Buy	+6,254	New	+$407K	﹤0.01%	1736

Other funds holding EGRX

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

BIP

Brandes Investment Partners La Jolla, California $14.1B AUM 25.52% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return

LSV Asset Management Chicago, Illinois $55.1B AUM 45.38% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

Metropolitan Life Insurance Company (MetLife)'s EGRX Position: Q4 2023 in Review

Metropolitan Life Insurance Company (MetLife) sold out of Eagle Pharmaceuticals, Inc. (EGRX) in Q4 2023, closing a stake of 556 shares — an estimated $8.77K sold.

Metropolitan Life Insurance Company (MetLife) first reported a position in EGRX in Q2 2015 and held it in 34 quarters. The position peaked at $553K in Q4 2015. 104 funds tracked by Wall St. Rank hold EGRX as of Q4 2023.

Metropolitan Life Insurance Company (MetLife) reported no remaining Eagle Pharmaceuticals, Inc. position as of Q4 2023 after selling out during the quarter.
Metropolitan Life Insurance Company (MetLife) sold 556 Eagle Pharmaceuticals, Inc. shares in Q4 2023, an estimated $8.77K.
Metropolitan Life Insurance Company (MetLife) first reported a position in Eagle Pharmaceuticals, Inc. in Q2 2015 and held it in 34 quarters.
Metropolitan Life Insurance Company (MetLife)'s Eagle Pharmaceuticals, Inc. position peaked at $553K in Q4 2015.
104 funds tracked by Wall St. Rank held Eagle Pharmaceuticals, Inc. as of Q4 2023.

Based on Metropolitan Life Insurance Company (MetLife)'s 13F filing for Q4 2023, filed 14 Feb 2024.